CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling [Seeking Alpha]
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? [Yahoo! Finance]
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "market perform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $3.25 price target on the stock.
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town [Seeking Alpha]